Shots:
- Daiichi Sankyo has dosed the first patient with DS3790 in the P-I/II trial for pts with r/r B-cell non-Hodgkin lymphoma
- The trial will assess DS3790 in ~420 pts with r/r B-cell NHL, evaluating safety endpoints as well as efficacy endpoints incl. overall response, DCR, DoR, time to response, PFS, & OS
- DS3790 is a CD37-targeted ADC built on Daiichi Sankyo’s DXd technology, combining a humanized anti-CD37 IgG1 antibody with cleavable linkers delivering exatecan-derived topoisomerase I inhibitor payloads
Ref: Businesswire  |  Image: Daiichi Sankyo |  Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
